LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer , but was never marketed.^[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.^[1]

References[edit]